share_log

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?

为什么生物-疫苗开发商Elicio Therapeutics的股票周五交易走低?
Benzinga ·  06/28 11:41

Thursday, Elicio Therapeutics Inc (NASDAQ:ELTX) released new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P.

2024年5月24日,Elicio Therapeutics公司(纳斯达克股票代码:ELTX)发布了其非个性化调查治疗癌症疫苗候选ELI-002 7P进行的AMPLIFY-7P 1a期研究的最新初步数据。

The preliminary data showed patients receiving ELI-002 7P at the Phase 2 dose of 4.9mg AMP-peptide were yet to reach the median disease-free survival (DFS) endpoint as of the May 24, 2024 data cutoff date.

初步数据显示,截至2024年5月24日截止日期,接受4.9毫克AMP-肽剂量的ELI-002 7P的患者尚未达到中位无疾病生存(DFS)终点。

The AMPLIFY-7P study is evaluating the 7-peptide formulation ELI-002 7P in patients with mKRAS-driven solid tumors following standard locoregional treatment.

AMPLIFY-7P研究评估标准治疗后mKRAS驱动的实体瘤患者中的7肽配方ELI-002 7P。

Data were based on May 24, 2024, data cutoff date of 14 patients with minimal residual disease who enrolled in the Phase 1 cohort of the AMPLIFY-7P study, with a median follow-up for the DFS endpoint of 29.1 weeks:

数据基于AMPLIFY-7P研究1期队列中14例最小残留病人的2024年5月24日数据截止日期,DFS终点的中位随访时间为29.1周。

The median DFS has not yet been reached (n=14).

中位DFS尚未达到(n = 14)。

The median disease-free survival (mDFS) has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-peptide dose (n=6).

接受4.9毫克AMP-肽剂量(n=8)的患者与接受1.4毫克AMP-肽剂量(n=6)的患者相比,中位无病生存期(mDFS)尚未达到。

Patients achieving a reduction in their tumor biomarker levels had no progression events, compared to an mDFS of 11.0 weeks for patients whose tumor biomarker did not respond to ELI-002 7P.

癌症生物标志物水平降低的患者没有进展事件,而那些病灶生物标志物没有对ELI-002 7P作出反应的患者的mDFS为11.0周。

Patients with an above-median T-cell response to ELI-002 have had no progression events.

具有高于中位数的T细胞反应的患者的进展情况良好。

The company expects to share additional clinical data updates from the AMPLIFY Phase 1 trials later in 2024 and the randomized Phase 2 interim analysis in the first quarter of 2025.

该公司预计将在2024年晚些时候分享AMPlIFY 1期试验的额外临床数据更新,并在2025年第一季度分享随机化2期中期分析的数据。

ELI-002 2P (2-peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors following surgery and chemotherapy.

ELI-002 2P(2肽剂型)目前正在一项进行中的1期(AMPLIFY-201)试验中研究高复发风险mKRAS驱动的实体瘤患者,这些患者曾接受手术和化疗。

ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer.

ELI-002 7P(7肽配方)目前正在一项1/2期(AMPLIFY-7P)试验中研究mKRAS驱动的胰腺癌患者。

Concurrently, Elicio Therapeutics priced its approximately $11.5 million public offering of 500k shares and accompanying warrants to purchase 500k shares at a combined price of $5.00.

与此同时,Elicio Therapeutics定价其约1150万美元的公开发行500,000股股票和可购买500,000股股票的认股权证,总价为5.00美元。

Price Action: ELTX shares are down 36.9% at $4.345 at last check Friday.

ELTX股票价格上涨,最后一次查询为4.345美元,下跌了36.9%。

Image by PDPics from Pixabay

来自Pixabay的PDPics图片

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发